Cargando…
Zavegepant nasal spray for the acute treatment of migraine: A meta analysis
BACKGROUND: Zavegepant nasal spray is a novel CGRP receptor antagonist that has been developed for the acute treatment of migraine – a prevalent disease leading to disability and economic burden. The meta-analysis aims to quantify the efficacy of Zavegepant compared to standard care or placebo in ac...
Autores principales: | Waqas, Muhammad, Ansari, Faizan Ur Rehman, Nazir, Anam, Hussain, Khadija Saleem Raza, Sarfraz, Zouina, Sarfraz, Azza, Sarfraz, Muzna, KC, Manish |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10615551/ https://www.ncbi.nlm.nih.gov/pubmed/37904462 http://dx.doi.org/10.1097/MD.0000000000035632 |
Ejemplares similares
-
Nasal spray (Zavegepant) for migraines: a mini-review
por: Larik, Muhammad Omar, et al.
Publicado: (2023) -
Neurokinin 1/3 receptor antagonists for menopausal women: A current systematic review and insights into the investigational non-hormonal therapy
por: Hassan, Fatima, et al.
Publicado: (2023) -
Gender-based violence in Pakistan and public health measures: a call to action
por: Sarfraz, Azza, et al.
Publicado: (2022) -
Ripple Collision of Three Epidemics: Vaping, Opioid Use, and COVID-19
por: Sarfraz, Zouina, et al.
Publicado: (2021) -
Tocilizumab and COVID-19: a meta-analysis of 2120 patients with severe disease and implications for clinical trial methodologies
por: SARFRAZ, Azza, et al.
Publicado: (2021)